PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
25344740-6	2014	Either pharmacological reconstitution of FoxO1 activity using intravenous or inhaled paclitaxel, or reconstitution of the transcriptional activity of FoxO1 by gene therapy, restored the physiologically quiescent PASMC phenotype in vitro, linked to changes in cell cycle control and bone morphogenic protein receptor type 2 (BMPR2) signaling, and reversed vascular remodeling and right-heart hypertrophy in vivo.	pasmc	212-217	bone morphogenetic protein receptor type 2	Homo sapiens	282-322	
25344740-6	2014	Either pharmacological reconstitution of FoxO1 activity using intravenous or inhaled paclitaxel, or reconstitution of the transcriptional activity of FoxO1 by gene therapy, restored the physiologically quiescent PASMC phenotype in vitro, linked to changes in cell cycle control and bone morphogenic protein receptor type 2 (BMPR2) signaling, and reversed vascular remodeling and right-heart hypertrophy in vivo.	pasmc	212-217	bone morphogenetic protein receptor type 2	Homo sapiens	324-329	
23525442-6	2013	As RAGE is one of the most upregulated proteins in PAH patients" lungs and a strong STAT3 activator, we hypothesized that by activating STAT3, RAGE induces BMPR2 and PPARgamma downregulation, promoting PAH-PASMC proliferation and resistance to apoptosis.	pasmc	206-211	bone morphogenetic protein receptor type 2	Homo sapiens	156-161	
22688668-10	2013	In sum, these results indicate that generally both receptors are reduced in PAH particularly ETB, and that ETB signaling through protein kinases becomes markedly reduced in BMPR2 PASMC, while it continues in IPAH.	pasmc	179-184	bone morphogenetic protein receptor type 2	Homo sapiens	173-178	
17142350-2	2007	Decreased BMPR2 expression and impaired intracellular BMP signaling in pulmonary artery (PA) smooth muscle cells (PASMC) suppresses apoptosis and promotes proliferation, thereby contributing to the pathogenesis of PAH.	pasmc	114-119	bone morphogenetic protein receptor type 2	Homo sapiens	10-15	
22718766-4	2012	Here we report the BMPR2-dependent repression of a set of inflammatory mediators in response to BMP4 stimulation of PASMC.	pasmc	116-121	bone morphogenetic protein receptor type 2	Homo sapiens	19-24	
27816994-7	2016	PMECs from BMPR2 mutation carriers induced an increase in PASMC mitogenic activity; moreover, endothelin-1 secretion by PMECs from carriers was higher than by PMECs from non-carriers.	pasmc	58-63	bone morphogenetic protein receptor type 2	Homo sapiens	11-16	
28828907-6	2017	PASMC have reduced inflammatory activation in response to IL-1ss compared with AoSMCs; however, PASMC with reduced BMPR2 demonstrated an exaggerated response.	pasmc	96-101	bone morphogenetic protein receptor type 2	Homo sapiens	115-120	
28084316-4	2017	TNFalpha-mediated suppression of BMPR-II subverts BMP signalling, leading to BMP6-mediated PASMC proliferation via preferential activation of an ALK2/ACTR-IIA signalling axis.	pasmc	91-96	bone morphogenetic protein receptor type 2	Homo sapiens	33-40	
30453304-10	2018	CONCLUSION: Our study indicates that SphK1/S1P pathway plays an important role in PDGF-induced PASMC proliferation via miR-21/BMPRII/Id1 axis and targeting against SphK1/S1P axis might be a novel strategy in the prevention and treatment of pulmonary arterial hypertension (PAH).	pasmc	95-100	bone morphogenetic protein receptor type 2	Homo sapiens	126-132	
28187784-16	2017	CONCLUSIONS: Collectively, this study suggests that MSCs modified with let-7a may ameliorate the progression of PAH by inhibiting PASMC growth through the STAT3-BMPR2 signaling, supporting a promising therapeutic strategy for PAH patients.	pasmc	130-135	bone morphogenetic protein receptor type 2	Homo sapiens	161-166